医学
闭塞性细支气管炎
转录组
肺
支气管肺泡灌洗
肺移植
表型
病理
基因表达谱
疾病
细胞外基质
基因
免疫
免疫学
内型
移植
先天免疫系统
分子诊断学
分子病理学
生物信息学
基因签名
呼吸道疾病
候选基因
进行性疾病
作者
Hanne Beeckmans,Pieterjan Kerckhof,Vincent Geudens,Cedric Vanluyten,Marta Zapata‐Ortega,Lynn Willems,Anke Van Herck,Astrid Vermaut,Gitte Aerts,Charlotte Hooft,Xin Jin,Jan Van Slambrouck,Andrea Zajacová,Martina Mercurio,Emanuela Elsa Cortesi,Yousry Khaled Mohamed Elmahdy Mohamady,Birger Tielemans,Christiane Knoop,Wim Janssens,Ghislaine Gayan‐Ramirez
出处
期刊:The European respiratory journal
[European Respiratory Society]
日期:2026-07-02
卷期号:68 (4): 2502380-2502380
被引量:4
标识
DOI:10.1183/13993003.02380-2025
摘要
BACKGROUND: Chronic lung allograft dysfunction (CLAD) is the leading cause of late mortality after lung transplantation. Bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS) are the main underlying clinical entities. Their molecular and cellular signatures are unclear and, therefore, we aimed to identify molecular programmes associated with morphological disease severity in CLAD. METHODS: We performed high-resolution imaging-based gene expression profiling of 128 lung samples from explanted CLAD and donor lungs, using weighted gene co-expression network analysis, cellular and pathway enrichment, and hub gene identification. Findings were validated across four datasets, including a murine transplant model, human BOS lungs, transbronchial biopsies, and bronchoalveolar lavage fluid of lung transplant recipients. RESULTS: Unsupervised clustering revealed two transcriptomic CLAD endotypes aligning with mild-fibrotic (BOS, mild RAS) and advanced-fibrotic disease (moderate/severe RAS). Samples from the same patient often diverged molecularly, underscoring intrapatient heterogeneity and limitations of current phenotypical classification. Five molecular programmes emerged: 1) epithelial stress and innate immunity in early-fibrotic CLAD; 2) progressive adaptive immunity and cytotoxicity in advanced CLAD; 3) transient extracellular matrix remodelling; 4) progressive endothelial loss/dysfunction; and 5) progressive loss of homeostasis, wherein multiple potential druggable targets were detected. Finally, we identified a 26 CLAD-hub-gene panel, which showed robust diagnostic performance to discriminate CLAD. CONCLUSION: CLAD is a spatially heterogeneous, yet molecularly continuous disease process, wherein BOS and RAS represent variable stages of a shared immunopathological continuum. Our findings support the development of lung-specific molecular classifiers to guide diagnostics and reveal novel targets for personalised therapies in transplantation.
科研通智能强力驱动
Strongly Powered by AbleSci AI